Dieras, Veronique <br/><br/>
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.  [electronic resource] 

 -  Anticancer research  03 2017 
 - 1403-1407 p.  digital 
<br/><br/> Publication Type: Journal Article; Observational Study 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Standard No.: </label>10.21873/anticanres.11462  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>France<br/>Humans<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Paclitaxel--administration & dosage<br/>Prognosis<br/>Prospective Studies<br/>Receptor, ErbB-2--metabolism<br/>Retrospective Studies<br/>Treatment Outcome<br/>Triple Negative Breast Neoplasms--drug therapy